Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Children with HIV are not small adults: what is different in pharmacology?

Children with HIV are not small adults: what is different in pharmacology? Children with HIV are not small adults: what is different in pharmacology? a,b b,c d a,b Rafae ¨ lla L’homme , Adilia Warris , Diana Gibb and David Burger Abbreviations Purpose of review The pharmacokinetics of antiretroviral drugs are highly BSA body surface area FDC fixed-dose combination variable among HIV-infected children. This review describes GFR glomerular filtration rate pharmacokinetic processes in children and recent NNRTI non-nucleoside reverse transcriptase inhibitor NRTI nucleoside reverse transcriptase inhibitor pharmacokinetic data in children with HIV. The general lack TDM therapeutic drug monitoring of pharmacokinetic data and the potential role of therapeutic drug monitoring are discussed. 2007 Lippincott Williams & Wilkins Recent findings 1746-630X It was found unexpectedly that exposure to lopinavir is decreased in the first 6 months of life. Recent findings of subtherapeutic efavirenz concentrations in children suggest Introduction that pediatric dose recommendations should be re- HIV-infected children cannot simply be regarded as evaluated. In addition, recommended dosing of lamivudine small adults, pharmacologically speaking. Pharmacoki- leads to lower exposure in children younger than 6 years of netics of antiretroviral drugs are highly variable in the age. Preliminary results of pediatric fixed-dose combination pediatric population as children mature and grow rapidly tablets for HIV-infected http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Children with HIV are not small adults: what is different in pharmacology?

Current Opinion in HIV and Aids , Volume 2 (5) – Sep 1, 2007

Loading next page...
 
/lp/wolters-kluwer-health/children-with-hiv-are-not-small-adults-colon-what-is-different-in-h7Ump1onz0

References (34)

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e3282ced13f
pmid
19372919
Publisher site
See Article on Publisher Site

Abstract

Children with HIV are not small adults: what is different in pharmacology? a,b b,c d a,b Rafae ¨ lla L’homme , Adilia Warris , Diana Gibb and David Burger Abbreviations Purpose of review The pharmacokinetics of antiretroviral drugs are highly BSA body surface area FDC fixed-dose combination variable among HIV-infected children. This review describes GFR glomerular filtration rate pharmacokinetic processes in children and recent NNRTI non-nucleoside reverse transcriptase inhibitor NRTI nucleoside reverse transcriptase inhibitor pharmacokinetic data in children with HIV. The general lack TDM therapeutic drug monitoring of pharmacokinetic data and the potential role of therapeutic drug monitoring are discussed. 2007 Lippincott Williams & Wilkins Recent findings 1746-630X It was found unexpectedly that exposure to lopinavir is decreased in the first 6 months of life. Recent findings of subtherapeutic efavirenz concentrations in children suggest Introduction that pediatric dose recommendations should be re- HIV-infected children cannot simply be regarded as evaluated. In addition, recommended dosing of lamivudine small adults, pharmacologically speaking. Pharmacoki- leads to lower exposure in children younger than 6 years of netics of antiretroviral drugs are highly variable in the age. Preliminary results of pediatric fixed-dose combination pediatric population as children mature and grow rapidly tablets for HIV-infected

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: Sep 1, 2007

There are no references for this article.